ST-elevation myocardial infarction: New Zealand management guidelines.
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002309:Cardiology / Q000592:standards*; D000077144:Clopidogrel; D000075202:Contraindications; D003402:Creatine Kinase / Q000097:blood; D016903:Drug Monitoring / Q000592:standards; D004452:Echocardiography; D004562:Electrocardiography; D019317:Evidence-Based Medicine / Q000379:methods; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis* / Q000628:therapy*; D009204:Myocardial Revascularization / Q000592:standards; D009520:New Zealand; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment / Q000379:methods; D015912:Thrombolytic Therapy / Q000592:standards; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014336:Troponin / Q000097:blood
D015415:Biomarkers; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014336:Troponin; D000077144:Clopidogrel; D003402:Creatine Kinase; D013988:Ticlopidine; D001241:Aspirin